Literature DB >> 27568482

Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

Emanuele Zaffuto1, Pierre I Karakiewicz2, Umberto Capitanio3.   

Abstract

Entities:  

Year:  2016        PMID： 27568482      PMCID： PMC4980377          DOI： 10.21037/atm.2016.06.25

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

Review 1.  Renal cancer.

Authors:  Umberto Capitanio; Francesco Montorsi
Journal:  Lancet       Date:  2015-08-25       Impact factor: 79.321

Review 2.  Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

Authors:  Marina Parton; Martin Gore; Tim Eisen
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

3.  High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.

Authors:  Michael Hanzly; Ahmed Aboumohamed; Naveen Yarlagadda; Terrance Creighton; Lorenzo Digiorgio; Ariel Fredrick; Gaurav Rao; Diana Mehedint; Saby George; Kristopher Attwood; Eric Kauffman; Deepika Narashima; Nikhil I Khushalani; Roberto Pili; Thomas Schwaab
Journal:  Urology       Date:  2014-05       Impact factor: 2.649

Review 4.  Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

Authors:  Roberto Iacovelli; Daniele Alesini; Antonella Palazzo; Patrizia Trenta; Matteo Santoni; Laura De Marchis; Stefano Cascinu; Giuseppe Naso; Enrico Cortesi
Journal:  Cancer Treat Rev       Date:  2013-09-11       Impact factor: 12.111

5.  Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Authors:  Alexandr Poprach; Zbyněk Bortlíček; Tomáš Büchler; Bohuslav Melichar; Radek Lakomý; Rostislav Vyzula; Petr Brabec; Marek Svoboda; Ladislav Dušek; Jakub Gregor
Journal:  Med Oncol       Date:  2012-06-30       Impact factor: 3.064

Review 6.  Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Authors:  Manuela Schmidinger; Joaquim Bellmunt
Journal:  Cancer Treat Rev       Date:  2010-02-16       Impact factor: 12.111

7.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

Review 8.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

Review 9.  Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.

Authors:  Lorena Incorvaia; Giuseppe Bronte; Viviana Bazan; Giuseppe Badalamenti; Sergio Rizzo; Gianni Pantuso; Clara Natoli; Antonio Russo
Journal:  Oncotarget       Date:  2016-04-19

Review 10.  Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Authors:  Stefanie Fischer; Silke Gillessen; Christian Rothermundt
Journal:  Transl Androl Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.